BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, November 24, 2024
Breaking News: Healing a health divide (that’s long overdue)
See today's BioWorld Science
Home
» Allogeneic anti-CD19 CAR T-cell therapy safe, effective in preclinical models
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immune
Allogeneic anti-CD19 CAR T-cell therapy safe, effective in preclinical models
June 18, 2024
No Comments
KYV-201 is an investigational allogeneic anti-CD19 CAR T-cell therapy candidate being developed by Kyverna Therapeutics Inc. for the treatment of B-cell-driven autoimmune diseases.
BioWorld Science
Conferences
CAR T
Immune
